The Dow Jones Industrial Average added 308 points, or 1%. The S&P 500 and the Nasdaq Composite gained 0.7% and 0.9%, respectively.

Several strong earnings reports were supporting the market, with AT&T and IBM rising 9% and 4.5%, respectively, after beating estimates on the top and bottom lines for their most recent quarter.

Mullen Automotive, Inc. (NASDAQ:MULN) shares are up another 13% today. The stock is surging after said the U.S. Bankruptcy Court approved its acquisition of electric vehicle company ELMS’ (Electric Last Mile Solutions) assets in an all-cash purchase.

HOOKIPA Pharma Inc. (HOOK) is currently trading at $1.5175 up +0.3075 (+25.4132%). HOOK announced today a strategic collaboration and license agreement with Roche to develop HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. This represents HOOKIPA’s first oncology licensing collaboration

A small cap company that we would like to draw your attention to is Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF). HLRTF is a clean technology company developing transformative power conversion technologies and control system solutions for next-generation electrical systems, announces it has signed a memorandum of understanding (MOU) with a global Tier 1 automotive leader in mobility innovation. According to the terms of the MOU, Hillcrest and the supplier will collaborate to integrate an optimized version of Hillcrest’s 250-kilowatt (kW), 800-Volt (V) inverter into a future powertrain system. The joint project is expected to run through 2023.

“Our partner is an early leader in electrification and has a shared understanding that efficiency is at the core of our electrified future,” said Hillcrest CEO Don Currie. “We are thrilled to collaborate on a project that could become the basis for many future products.” Read more at

Another stock that is gaining traction today is GOSS. Analyst Paul Choi initiated coverage of Gossamer Bio (NASDAQ:GOSS) with a buy rating and a $22 price target, calling attention to upcoming results from the company’s second phase trial of its seralutinib drug as a treatment for pulmonary arterial hypertension, a type of high blood pressure that can be life-threatening.

Disclaimer: InvestorBrandMedia is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available in this article is not intended to be, nor does it constitute investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report, and publication. In no event shall InvestorBrandMedia be liable to any member, guest, or third party for any damages of any kind arising out of the use of any content or other material published or made available by InvestorBrandMedia ., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Investor Brand Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. InvestorBrandMedia has been compensated by a 3rd party Bullyzeye Media LLC for content, research, dissemination, and syndication pertaining to HLRTF for 10/20/2022. We own zero shares of HLRTF

Leave a Reply

Your email address will not be published. Required fields are marked *